Institut National de la Santé et de la Recherche Médicale Unité 872, Paris, France.
Clin Exp Immunol. 2011 Jun;164 Suppl 2(Suppl 2):2-5. doi: 10.1111/j.1365-2249.2011.04387.x.
Intravenous immunoglobulin (IVIG) is a therapeutic compound prepared from pools of plasma obtained from several thousand healthy blood donors. For more than 20 years, IVIG has been used in the treatment of a wide range of primary and secondary immunodeficiencies. IVIG now represents a standard therapeutic option for most antibody deficiencies. Routinely, IVIG is used in patients with X-linked agammaglobulinaemia (XLA), common variable immunodeficiency (CVID), X-linked hyper-IgM, severe combined immunodeficiency, Wiskott-Aldrich syndrome, and selective IgG class deficiency. In addition, IVIG is used extensively in the treatment of a wide variety of autoimmune disorders. IVIG is administered at distinct doses in the two clinical settings: whereas immunodeficient patients are treated with replacement levels of IVIG, patients with autoimmune and inflammatory diseases are administered with very high doses of IVIG. Several lines of experimental evidence gathered in the recent years suggest that the therapeutic beneficial effect of IVIG in immunodeficiencies reflects an active role for IVIG, rather than a mere passive transfer of antibodies.
静脉注射免疫球蛋白（IVIG）是一种从数千名健康献血者的血浆中制备的治疗性化合物。 20 多年来，IVIG 已被用于治疗各种原发性和继发性免疫缺陷。 IVIG 现在是大多数抗体缺陷的标准治疗选择。通常，IVIG 用于 X 连锁无丙种球蛋白血症（XLA）、常见可变免疫缺陷（CVID）、X 连锁高 IgM、严重联合免疫缺陷、Wiskott-Aldrich 综合征和选择性 IgG 类缺陷患者。此外，IVIG 在治疗各种自身免疫性疾病中也得到广泛应用。 IVIG 在两种临床情况下以不同剂量给药：免疫缺陷患者接受 IVIG 的替代剂量治疗，而自身免疫和炎症性疾病患者则接受非常高剂量的 IVIG。近年来收集的几条实验证据表明，IVIG 在免疫缺陷中的治疗有益效果反映了 IVIG 的积极作用，而不仅仅是抗体的被动转移。
